Genmab Announces U.S. FDA Approval of DARZALEX(TM) (daratumumab) for Multiple Myeloma and Updates Financial Guidance

Company Announcement DARZALEX (daratumumab) approved by U.S. FDA for heavily pre-treated or double refractory multiple myeloma First monoclonal antibody approved for multiple myeloma Financial guidance updated to include USD 45 million milestone payment COPENHAGEN, Denmark, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today the U.S. Food and Drug Administration (FDA) has approved DARZALEX(tm) (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double-refractory to a PI...